Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Life Science

• Publication date

  1997-03-07

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0024-3205(97)00067-2PMID 9096240
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age.

  2008cited by this paper
• Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: putative implications for psychiatry and psychopharmacology

  2004cited by this paper
• On the Origin of Extracellular Glutamate Levels Monitored in the Basal Ganglia of the Rat by In Vivo Microdialysis

  1996cited by this paper
• Selective neuroanatornic abnormalities in Down's syndrome and their cognitive correlates

  1995cited by this paper
• Cognitive impairment in adults with Down's syndrome

  1994cited by this paper
• Magnetic resonance imaging analysis of age‐related changes in the brains of individuals with Down's syndrome

  1994cited by this paper
• Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization.

  1994cited by this paper
• Frontal lobes and behaviour.

  1994cited by this paper
• Neuronal dependence of extracellular dopamine, acetylcholine, glutamate, aspartate and gamma-aminobutyric acid (GABA) measured simultaneously from rat neostriatum using in vivo microdialysis: reciprocal interactions

  1992cited by this paper
• Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology.

  1992cited by this paper
• Parallels between Down syndrome dementia and Alzheimer's disease.

  1992cited by this paper
• Excitatory amino acid transmitters and their receptors in neural circuits of the cerebral neocortex.

  1990cited by this paper
• Hippocampal plasticity in normal aging and decreased plasticity in Alzheimer's disease.

  1990cited by this paper
• Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease.

  1990cited by this paper
• Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex.

  1989cited by this paper
• Reduced D-[3H]aspartate binding in Down's syndrome brains.

  1989cited by this paper
• Dementia in Down's syndrome

  1988cited by this paper
• Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue.

  1988cited by this paper
• The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

  1987cited by this paper
• Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides.

  1987cited by this paper
• Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.

  1987cited by this paper
• In Vivo Release of Endogenous Amino Acids from the Rat Striatum: Further Evidence for a Role of Glutamate and Aspartate in Corticostriatal Neurotransmission

  1986cited by this paper
• Effect of Cortico‐Striate Pathway Lesion on the Activities of Enzymes Involved in Synthesis and Metabolism of Amino Acid Neurotransmitters in the Striatum

  1985cited by this paper
• Alzheimer-like brain monoamine deficits in adults with Down's syndrome.

  1985cited by this paper
• Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome

  1985cited by this paper
• Glutamate: A Neurotransmitter in Mammalian Brain

  1984cited by this paper
• Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey.

  1984cited by this paper
• Differential amino acid neurotransmitter release in rat neostriatum following lesioning of the cortico-striatal pathway.

  1982cited by this paper
• Alzheimer's Disease and Down's Syndrome *

  1982cited by this paper
• Alzheimer-like cholinergic deficiency in Down syndrome.

  1980cited by this paper
• THE METABOLISM OF FATTY ACIDS IN THE RAT. VI. ARACHIDONIC ACID.

  1965cited by this paper
• DYNAMIC RESPONSE OF CHEST WALL AND LUNG INJURIES IN RABBITS EXPOSED TO AIR SHOCK WAVES OF SHORT DURATION.

  1964cited by this paper

• Complement pathway dysregulation and astrocyte alterations in Down syndrome: evidence from postmortem brain tissue and iPSC-derived astrocytes

  2025cites this paper
• A Dive Into Cerebellar Dysfunction, Motor Deficits and GABAergic Signaling in Down Syndrome

  2025cites this paper
• ZBTB21 suppresses CRE-mediated transcription to impair synaptic function in Down syndrome

  2024cites this paper
• Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  2023cites this paper
• Ts65Dn synaptic proteome partially recapitulates AD biochemical signature

  2023cites this paper
• Rutin, Puerarin and Silymarin Regulated Aluminum-Induced Imbalance of Neurotransmitters and Metal Elements in Brain of Rats

  2023cites this paper
• Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  2023cites this paper
• Brain circuit pathology in Down syndrome: from neurons to neural networks

  2022cites this paper
• Children With Trisomy 21 and Lennox-Gastaut Syndrome With Predominant Myoclonic Seizures

  2021cites this paper
• Rethinking Intellectual Disability from Neuro- to Astro-Pathology

  2020cites this paper
• Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome.

  2020cites this paper
• Biomarkers for pediatric cancer detection: latest advances and future perspectives.

  2020cites this paper
• Microfluidic neurotransmitters sensor in blood plasma with mediator-immobilized conducting polymer/N, S-doped porous carbon composite

  2020cites this paper
• Cognitive function in mice with segmental trisomy of human chromosome 21 Down Syndrome genes

  2019cites this paper
• Down syndrome: Neurobiological alterations and therapeutic targets

  2019cites this paper
• Human astrocytes in the diseased brain

  2018cites this paper
• Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain

  2018cites this paper
• RCAN1 Knockdown Reverts Defects in the Number of Calcium-Induced Exocytotic Events in a Cellular Model of Down Syndrome

  2018cites this paper
• Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome

  2018cites this paper
• Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.

  2017cites this paper
• Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models

  2017influential citation
• Ts1Cje Down syndrome model mice exhibit environmental stimuli‐triggered locomotor hyperactivity and sociability concurrent with increased flux through central dopamine and serotonin metabolism

  2017influential citation
• Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues

  2017cites this paper
• Glutamatergic synapses in neurodevelopmental disorders

  2017cites this paper
• Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

  2017cites this paper
• Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease

  2017cites this paper
• Mental Retardation and Human Chromosome 21 Gene Overdosage : From Functional Genomics and Molecular Mechanisms Towards Prevention and Treatment of the Neuropathogenesis of Down Syndrome

  2017cites this paper
• Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome

  2016cites this paper
• Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome

  2016cites this paper
• Hydrophilic interaction chromatography combined with dispersive liquid-liquid microextraction as a preconcentration tool for the simultaneous determination of the panel of underivatized neurotransmitters in human urine samples.

  2016cites this paper
• VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome

  2016cites this paper
• III. Botenstoffe und Neuro-Enhancement

  2016cites this paper
• Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy.

  2015cites this paper
• Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome.

  2015cites this paper
• New Perspectives for the Rescue of Cognitive Disability in Down Syndrome

  2015cites this paper
• Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.

  2014cites this paper
• Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy (1H MRS)

  2014cites this paper
• Pharmacological Rescue of Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome

  2014cites this paper
• Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome

  2014influential citation
• Altered Distribution of Hippocampal Interneurons in the Murine Down Syndrome Model Ts65Dn

  2014cites this paper
• Long‐term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle‐aged Ts65Dn mice, a model of Down syndrome

  2013cites this paper
• Molecular Pathways of Down Syndrome Critical Region Genes

  2013cites this paper
• Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction via modulation of glutamate receptor recycling in Down syndrome

  2013cites this paper
• Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.

  2012cites this paper
• Sonic Hedgehog pathway impairment in Neural Precursor Cells of the Ts65Dn mouse, an animal model of Down syndrome

  2012cites this paper
• Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

  2012cites this paper
• Is it possible to improve neurodevelopmental abnormalities in Down syndrome?

  2011cites this paper
• Combinatorial Gene Effects on the Neural Progenitor Pool in Down Syndrome

  2011cites this paper
• Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer’s disease

  2011cites this paper
• Mental Retardation and Human Chromosome 21 Gene Overdosage: From Functional Genomics and Molecular Mechanisms Towards Prevention and Treatment of the Neuropathogenesis of Down Syndrome

  2011cites this paper
• Implication for treatment : GABA A receptors in aging , Down syndrome and Alzheimer ' s disease

  2011cites this paper
• G-Protein-Associated Signal Transduction Processes Are Restored after Postweaning Environmental Enrichment in Ts65Dn, a Down Syndrome Mouse Model

  2011cites this paper
• Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome.

  2010cites this paper
• Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

  2010influential citation
• Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome.

  2010cites this paper
• Determination of dansylated monoamine and amino acid neurotransmitters and their metabolites in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.

  2010cites this paper
• A quantitative assessment of gene expression (QAGE) reveals differential overexpression of DOPEY2, a candidate gene for mental retardation, in Down syndrome brain regions

  2009cites this paper
• Excitatory‐inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome

  2009cites this paper
• Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways.

  2008cites this paper
• Amino Acids Profile in Mentally Retarded Libyan Children

  2008cites this paper
• Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms.

  2007cites this paper
• C21orf5, a new member of Dopey family involved in morphogenesis, could participate in neurological alterations and mental retardation in Down syndrome.

  2005cites this paper
• C21orf5, a human candidate gene for brain abnormalities and mental retardation in Down syndrome

  2005cites this paper
• Spatial and temporal localization during embryonic and fetal human development of the transcription factor SIM2 in brain regions altered in Down syndrome

  2005cites this paper
• Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome.

  2004cites this paper
• Characterization of social behaviors and oxytocinergic neurons in the S-100 beta overexpressing mouse model of Down Syndrome.

  2003cites this paper
• Advances in Down Syndrome Research

  2003cites this paper
• The differentially expressed C21orf5 gene in the medial temporal-lobe system could play a role in mental retardation in Down syndrome and transgenic mice.

  2003cites this paper
• RNA microarray analysis of channels and transporters in normal and fetal Down syndrome (trisomy 21) brain.

  2003cites this paper
• Increased RNA levels of the 25 kDa synaptosomal associated protein in brain samples of adult patients with Down Syndrome.

  2003cites this paper
• Spectrum of cognitive, behavioural and emotional problems in children and young adults with Down syndrome.

  2003cites this paper
• Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down's syndrome cerebral cortex

  2002cites this paper
• The brain in Down syndrome.

  2001cites this paper
• Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure.

  2001cites this paper
• Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology

  2001influential citation
• Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation.

  2001cites this paper
• Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice.

  2000cites this paper
• Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease

  1999cites this paper
• c-fos expression in brains of patients with Down syndrome.

  1999cites this paper
• Serotonin (5-HT) in brains of adult patients with Down syndrome.

  1999cites this paper
• Brain vasopressin levels in Down syndrome and Alzheimer's disease.

  1998cites this paper